A leading R& D Biotech developing immunomodulatory drugs for the treatment of Autoimmune Diseases & Cancer. Innovoimmune Biotherapeutics, is developing proprietary oral small molecule immunomodulatory drugs targeting cytokine, chemokine and signal transduction pathways critical in the pathogenesis of Autoimmune Diseases and Cancer.
Innovimmune Biotherapeutics, Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttp://www.innovimmune.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address125 Maiden Lane,NY 10038New YorkUnited States
125 Maiden Lane,NY 10038
New York
United States
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/innovimmune-biotherapeutics-inc-” connections=”true” suffix=””]
In July 2014, Innovimmune was awarded a $3 Mn, three-year (2014-2017) National Institute of Health (NIH) Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the preclinical development. Prior this Innovimmune recieved several other NIH grants totalling nearly $1Mn for the development of its pipeline.